Waverly Capital

Camera IQ Inc. is a technology company based in Santa Monica, California, that specializes in augmented reality (AR) solutions for digital marketing. Founded in 2013, Camera IQ offers a camera experience management platform that integrates various operating system platforms, AR toolkits, and native applications. This platform enables marketers to create, manage, and measure large-scale AR campaigns that engage audiences across social media and streaming platforms. By providing intuitive drag-and-drop tools, Camera IQ allows brands to design captivating marketing experiences optimized for smartphone cameras, fostering deeper connections with customers and enhancing brand engagement.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.